Skip to main content

Table 1 Clinical characteristics for patients with ankylosing spondylitis participating in the study (n = 210)

From: Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study

Age (years) 49 (13)
Men/Women 120/90
BMI 26.0 (4.5)
Smoker ≥ 6 months 105 (50%)
Rheumatologic characteristics
  Age at symptom onset (years) 26 (10)
  Symptom duration (years) 24 (13)
  Diagnostic age (years) 36 (11)
  Diagnostic duration (years) 14 (11)
  BASDAI (score) 3.6 (2.1)
  BASFI (score) 2.7 (2.1)
  BASMI (score) 3.1 (1.6)
Blood tests
  HLA B27 n (%) 183* (87)
  Hemoglobin (g/L) 139 (13)
  White blood cell count (×109/L) 7.0 (2.2)
  Platelet count (×109/L) 298 (75)
  Erythrocyte sedimentation rate (mm/h) 15 (14)
  C-reactive protein (mg/L) 8.4 (10.2)
Concomitant diseases
  Diabetes mellitus 6 (2.9)
  Hyperlipidemia 17 (8.1)
  Hypertension 56 (27)
  Other cardiovascular diseases¶ 26 (12)
  Coronary artery disease 6 (2.9)
  Heart failure 4 (1.9)
  Valvular disease 6 (2.9)
  Arrhythmia 4 (1.9)
  Various not specified/ 10 (4.8)
  Stroke 4 (1.9)
Medication
  ACEI/ARB 23 (11)
  Analgesics 54 (26)
  Antiarrhythmic agents 3 (1.4)
  Antidiabetic agents 3 (1.4)
  Antihypertensive agents 15 (7.1)
  ASA 22 (11)
  Betablockers 28 (13)
  Calcium antagonists 7 (3.3)
  Digitalis 2 (1.0)
  Diuretics 15 (7.1)
  DMARD 77 (37)
  Lipid modulators 15 (7.1)
  NSAID 161 (77)
  TNF inhibitor 45 (21)
  Warfarin 2 (1.0)
  1. *11 were homozygous.
  2. ¶more than one is possible.
  3. Data regarding demographic, clinical and laboratory analyses are presented as mean (SD), while concomitant diseases and medication are presented in numbers (%).
  4. Abbreviations: ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, ASA acetylsalicylic acid, BMI body mass index, weight/height2, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, DMARD disease modifying antirheumatic drug, NSAID non-steroidal anti-inflammatory drugs, TNF tumour necrosis factor.